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Abstract In February 2014, the US Food and Drug
Administration (FDA) convened an advisory committee
meeting to discuss the accumulated data relating to the
cardiovascular risk of non-steroidal anti-inflammatory
drugs (NSAIDs) and the potential implications on the class
prescription labeling. The committee recommended,
though not unanimously, that (1) the current data does not
support the conclusion that naproxen has a lower risk of
thrombotic events than other NSAIDs; (2) there is no
latency period for the risk of cardiovascular thrombotic
events; (3) there are some patient populations at increased
risk for events; and (4) equipoise remains in the major
ongoing trial designed to address these issues further. The
clinical implications of the FDA deliberations as well as
the recently published meta-analyses and observational
studies are discussed. With the information available today,
there is insufficient evidence to conclude that there are
significant differences between the approved NSAIDs with
regard to the potential for cardiovascular events. An
approach for balancing the major risks associated with
NSAIDs is suggested. Clinicians should continue to use the
current FDA NSAID labeling language to guide their
decision making for individual patients until such time as
the FDA makes changes.
Key Points
New data from observational studies and meta-
analyses of randomized controlled trials have
suggested that naproxen may be associated with a
lower risk of cardiovascular thrombotic events as
compared to other NSAIDs.
An FDA advisory committee was convened to
review the new data, and a majority of the panel did
not find the data sufficient to suggest major
prescription labeling changes and suggested that
PRECISION, the major trial designed to address
these issues, continue unchanged.
1 Introduction
Prescription non-steroidal anti-inflammatory drug
(NSAID) use is prevalent in the USA, reflecting the aging
of the population and the concomitant rise in musculo-
skeletal diseases, particularly osteoarthritis (OA) and
rheumatoid arthritis (RA). From October 2011 to Septem-
ber 2012, the top five NSAIDs accounted for nearly 86
million dispensed prescriptions for 44 million unique
patients [1]. This level of use and acceptance reflects the
well-recognized anti-inflammatory and analgesic properties
of these agents. Historically, research had identified these
positive effects to be associated with inhibition of cyclo-
oxygenase (COX)-2-mediated inflammation as opposed to
COX-1, which is responsible for constitutive prostaglandin
synthesis that, among other things, protects the
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gastrointestinal (GI) track and affects platelet homeostasis.
As the prototypic NSAIDs block both COX-1 and COX-2
to varying degrees, both positive (anti-inflammatory/
analgesia) as well as negative (bleeding/GI complications)
effects could be expected. It was intuitive to pursue
research on this COX-2 hypothesis (preferential COX-2
inhibition while sparing COX-1 inhibition) to determine if
more effective or safer ways to balance the risks with the
benefits from NSAIDs could be uncovered.
Research began in the 1990s to better understand COX-
2 selectivity and culminated in the introduction of COX-2
selective inhibitors (coxibs), along with the hope that we
could push doses higher for greater anti-inflammatory
effect while reducing GI side effects and improving toler-
ability. Though not powered to show a difference in effi-
cacy, the large pivotal trials for the first two coxibs
available in the USA showed non-inferiority to the tradi-
tional non-selective NSAIDs (nsNSAIDs), ibuprofen, dic-
lofenac, and naproxen, in the treatment of OA [2–4],
reinforcing the general observation that at equivalent doses
all NSAIDs are equally efficacious. Coxib studies, how-
ever, demonstrated a reduction in the risk of NSAID-
induced adverse GI effects (particularly GI ulcers) com-
pared with nsNSAIDs, but pharmaceutical sponsors were
never able to provide compelling enough evidence to the
Food and Drug Administration (FDA) for formal label-
indicated approval of a reduction in GI complications [5–
7]. This lack of regulatory recognition of the benefits of
coxibs nevertheless did not temper their early acceptance in
the clinical community.
2 Cardiovascular (CV) Adverse Events and the ‘‘COX-
2 Hypothesis’’
In 2001, a study published in the New England Journal of
Medicine on the GI comparative safety of rofecoxib (the
second coxib approved in the USA) reported a myocardial
infarction (MI) rate significantly higher than that with
naproxen (0.4 vs. 0.1 %) [7]. Interestingly, the authors
concluded that the difference was likely due to a favorable
secondary cardiovascular (CV) protective effect of
naproxen on platelet function since the effect seemed to
occur in those who were at risk for CV events (i.e., were
candidates for cardioprotective doses of aspirin, but were
not receiving it). In the group that was not at risk for CV
events, there was no significant difference in the incidence
of MI between those who received naproxen or rofecoxib.
Additional data from this trial, which were released later,
indicated that rofecoxib did indeed carry an independent
thrombotic risk, especially as the dose increased [8, 9], and
that any benefit from the prevention of one complicated
upper GI event came at the cost of one serious thrombotic
event [9]. Rofecoxib was voluntarily removed from the
market in 2004 after the results of a placebo-controlled trial
found almost a doubling of serious CV events [10] and that
the risk was elevated up to a year after stopping the drug
[11]. Regulatory actions shortly occurred on other coxibs;
valdecoxib was removed from the market, and its prodrug,
parecoxib, received a non-approvable letter from the FDA
in 2005. Celecoxib remains the only coxib available on the
US market [1].
Many of the CV safety issues that this early foray into
COX-2-specific inhibition uncovered are still open, and
concerns have expanded to the NSAID class at large.
Among the nsNSAIDs, small differences in CV safety have
been observed, and the relative effects of the agents in this
class have been debated. The relative CV safety among the
class will remain a central question for clinicians and
regulators for the next decade.
3 FDA Advisory Meetings and History of Non-steroidal
Anti-inflammatory Drug (NSAID) Class Labeling
In 2005, the FDA held an advisory committee meeting to
discuss the data that had emerged from the coxib trials,
including data on drugs under development. Largely on the
basis of the trials discussed above with rofecoxib and those of
other drugs under development (etoricoxib, lumiracoxib),
the committee determined that all NSAIDs confer an
increased risk for serious and potentially life-threatening CV
events (defined as thrombotic events, MI, and stroke) and
that the data do not allow a rank ordering of risk potential [1].
On the basis of the discussion and recommendations
from the committee at that time, the FDA took the fol-
lowing key actions on all prescription NSAID labels,
adding (1) a ‘‘black box’’ warning highlighting the poten-
tial for increased risk for CV events and serious life-
threatening GI bleeding, ulceration, and perforation; (2)
statements indicating patients with, or at risk for, CV dis-
ease and the elderly may be at greater risk, and that these
reactions may increase with duration of use; (3) a contra-
indication for use after coronary artery bypass graft surgery
on the basis of reports with valdecoxib/parecoxib; (4)
language that the lowest dose should be used for the
shortest duration possible; and (5) wording in the warning
section that there is no evidence that the concomitant use of
aspirin with NSAIDs mitigates the CV risk, but that it does
increase the GI risk.
Furthermore, the FDA requested that Pfizer, the com-
pany that markets celecoxib, complete a post-marketing
trial to examine these issues in more detail, and the Pro-
spective Randomized Evaluation of Celecoxib Integrated
Safety versus Ibuprofen Or Naproxen (PRECISION) Trial
was started in 2006. The study was designed to examine the
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non-inferiority of celecoxib, naproxen, and ibuprofen on
first occurrence of a composite CV primary endpoint (CV
mortality, non-fatal MI, non-fatal stroke) among random-
ized OA or RA patients with, or at high risk for, CV disease
expected to need high-dose NSAID therapy [12]. Low-dose
aspirin and gastroprotective therapy with esomeprazole are
allowed as needed, and GI outcomes are to be monitored
prospectively. Patient enrollment had approached [95 %
(22,621) of target (23,750) as of February 2014, but the
event rate has been lower than expected and the power of
the study was reduced from 90 to 80 %, lowering the events
needed from 762 to 580 and extending the end date to
December 2015, 2 years later than originally planned [1].
In February 2014, the FDA convened another advisory
committee meeting based on recently published meta-
analyses and observational studies calling into question
some of the previous assumptions guiding the US NSAID
class labeling. In 2011, an observational study from the
Danish National Registry was published that indicated that
patients who had previously had an MI were at risk for
recurrent MI and death as early as 1 week after starting
NSAID therapy [13]. The authors concluded their report by
saying ‘‘neither short- nor long-term treatment with NSA-
IDs is advised in this population.’’ Furthermore, a meta-
analysis of randomized NSAID trials by the Coxib and
traditional NSAID Trialists’ (CNT) Collaboration pub-
lished in the Lancet in May 2013 concluded that ‘‘the
vascular risk of high-dose diclofenac, and possibly ibu-
profen, are comparable to coxibs, whereas high-dose
naproxen is associated with less vascular risk than other
NSAIDs. Although NSAIDs increase vascular and gastro-
intestinal risks, the size of these risks can be predicted,
which could help guide clinical decision making’’ [14].
Shortly after publication of this data, the European Medi-
cines Agency (EMA) revised the labeling of diclofenac to
be in line with that of coxibs, which have stronger pre-
scribing warnings than nsNSAIDs in Europe [15].
Pre-meeting materials for the 2014 advisory committee
meeting included FDA staff review of the published data,
including one from a Medical Officer in the Office for
Pharmacovigilance and Epidemiology, who concluded the
following [1]: (1) there appears to be less thrombotic CV
risk with naproxen and a higher risk with diclofenac as
compared with other nsNSAIDs; (2) CV risk is observable
from the beginning of NSAID therapy; (3) the relative risk
(RR) for NSAID-induced CV events is the same in healthy
individuals as in those at risk for CV events, but the
absolute risk is higher for those patients at risk for CV
events; (4) observational studies in aggregate indicate that
both nsNSAIDs and coxibs are associated with stroke,
albeit at a lower rate than MI, and there is no pattern of
relative hazard among the NSAIDs; (5) some evidence
exists that aspirin can decrease CV risk associated with
NSAIDs, but naproxen and ibuprofen (the most studied
NSAIDs) can inhibit the cardioprotection of aspirin when
administered in close time proximity; (6) there is some
evidence that naproxen may have a lower CV risk than
ibuprofen, but ibuprofen has lower GI risk than naproxen;
and (7) equipoise no longer exists in the PRECISION trial
and it should be stopped.
4 FDA Advisory Committee Discussion and Vote
on CV Issues
At the February 2014 meeting, background presentations
were presented by authors of the meta-analyses and
observational studies, FDA officials, industry representa-
tives, as well as guest speakers, including the lead inves-
tigator for the PRECISION trial. The following topics were
specifically discussed [1]:
4.1 Does the Accumulated Data Support a Clinically
Significant Difference in Risk for CV Thrombotic
Events for Any of the NSAIDs?
A number of panelists agreed that the data appear to sup-
port a differential risk with NSAIDs, although differing
study characteristics (unequal doses, acute/chronic use,
low/high CV risk, and aspirin use or not) complicate the
interpretation of the CNT meta-analysis. Most agreed that
the data were suggestive of a differential benefit with
naproxen but were not strong enough to support a label
claim, and the indirect NSAID comparison approach of the
CNT meta-analysis made some uncomfortable, especially
given that most of the confidence intervals overlapped. The
FDA addressed questions from the committee on the
appropriateness of using meta-analytic and observational
data to make changes in the prescribing labels. FDA
staffers echoed comments previously published in the
debriefing materials, that the use of observational and
meta-analytic studies informing regulatory decisions pre-
viously ‘‘were focused on evaluating efficacy rather than
safety. As such, these examples are not directly relevant to
a meta-analysis primarily done to assess harms, as in the
case of the CNT meta-analysis. The standard for estab-
lishing efficacy or clinical benefit based on clinical trials is
well established and is not based on meta-analysis. In
contrast, best practices for safety related meta-analysis of
clinical trials are not well established and the FDA has not
issued any Guidance on the subject’’ [1]. The committee
voted 16 to nine that the data do not support naproxen’s
lower CV thrombotic risk as compared with other NSAIDs.
Several panel members indicated they voted no because of
concerns that giving preferential CV labeling to naproxen
may inadvertently cause harm by increasing use and its
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associated GI risk. Several also pointed out that the option
of using it preferentially for appropriate patients exists as a
personal clinical decision presently.
4.2 Does the Weight of Evidence Support
Reconsideration of Advice Regarding the Latency
of CV Thrombotic Risk?
The committee voted 14 to 11 that the evidence indicates
that there is no time period where patients taking NSAIDs
may be considered to not be at CV risk. The majority of the
committee indicated that there is risk across time and the
labeling should reflect this. Those that disagreed indicated
that not all studies demonstrate this and many that do are
with pre-existing CV disease or at risk patients, on high
doses, and/or without low-dose aspirin (especially the
coxib studies).
4.3 Based on the Available Data, Is It Appropriate
to Consider Any Restrictions or Specific Warnings
for Those Populations Who Are at Higher Absolute
Risk for CV Thrombotic Events with NSAID Use?
Potential Options Include but Are Not Limited
to Extending the Contraindication in Certain
Subpopulations [e.g., Patients Immediately Post-
Myocardial Infarction (MI)] or Including
a Statement in the Boxed Warning Regarding
the Increased Absolute CV Thrombotic Risk
in the Post-MI or Heart Failure Populations
Most of the panel indicated that they agreed with the notion
of calling out patients at risk, but many were reluctant to
make specific population recommendations, with the
exception of post-MI and RA patients, who may be at higher
risk. In a large cohort study, even short-term treatment with
NSAIDs has been found to increase the risk for CV death and
recurrent MI in the post-MI patient population, and, there-
fore, these agents should be avoided if possible in this pop-
ulation [13]. In regard to heart failure, the committee mostly
supported specific labeling, on the basis of data from the
CNT meta-analysis, which indicated that all NSAIDs pre-
dispose to heart failure, but many were reluctant to suggest a
contraindication given the benefit in appropriate patients.
They agreed that those with coronary artery disease are at
risk and the prescription labeling should be strengthened in
this regard. A vote was not taken on this issue.
4.4 Are There Any Changes That Should Be Made
to the PRECISION Trial to Respond
to the Concerns That Have Been Raised?
Most panelists voiced support for equipoise between
treatment arms in the study, viewed it as an important trial,
and felt that it should not be stopped. While some
expressed concern about the design and whether it will
answer the question on differential CV risk, many sug-
gested it is the best chance to answer the question. Some
suggested that if there was evidence of harm, the study
would have been stopped by the safety monitoring com-
mittee and, therefore, it should continue. A vote was not
taken on this issue.
5 Clinical Implications
Although the FDA is yet to announce any changes in
NSAID prescribing labeling, they generally follow the
recommendations of the advisory committee. Given the
recent data and FDA discussions, what clinical conclusions
can we make? Among the FDA advisory committee, 36 %
of them were convinced that the current evidence justified
the conclusion that naproxen had a lower CV thrombotic
risk, and a few of them admitted that they would change
their prescribing habits on the basis of this data, but the
majority were not convinced [1].
One of the most controversial issues with the data is the
use of indirect comparisons in the calculation of the CV
hazard rate ratios (number of events/number of patient
years) in the CNT analysis [14]. Direct comparisons using
both trial- and patient-level data were used to calculate
these ratios for the coxibs versus placebo and nsNSAIDs.
On the contrary, a combination of direct and indirect
methods was used to compare individual nsNSAIDs to
placebo. The indirect method is acceptable in trials with
little heterogeneity [1]. An FDA statistical review found
that the CNT meta-analysis generally fit the acceptable
standards for such a method, with the exception of ‘indi-
cation for treatment differences’ which exists among the
coxib studies (Alzheimer’s and colon adenoma cancer
prevention) [1]. Importantly, the analysis provides only
comparative data of individual nsNSAIDs and coxibs
versus placebo and coxibs versus individual NSAIDs.
There are no direct or indirect comparisons among
individual nsNSAIDs in the report because of the lack of
randomized head-to-head trials, which is a key clinical
question. One way to estimate whether two risk ratios are
different from one another is the use of a ratio of relative
risk (RRR) calculation [16]. Using an RRR calculation on
the major vascular event RRs obtained in the CNT meta-
analysis for each of the nsNSAIDs versus placebo, one can
estimate that the data support the conclusion that diclofe-
nac’s risk is higher than naproxen’s, but that other com-
parisons are not significant (Table 1). This is not surprising
in that of the three nsNSAIDs studied, diclofenac is the
only one shown to have a higher CV risk than placebo in
the CNT analysis [14] and a higher CV mortality and
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morbidity in observational studies [17]. It is surprising
given these findings that more discussion at the FDA
advisory meeting was not centered on diclofenac, as the
data would seem to indicate that it has a CV risk similar to
that of rofecoxib, and is potentially deserving of stricter
labeling than the other nsNSAIDs, as the EMA has done.
Finally, an important issue of competing GI risk is
reported in the CNT meta-analysis and emphasizes the
need to put this in perspective when we are making clinical
decisions. The trials clearly show that coxibs statistically
significantly reduce the risk of upper GI complications
when compared with ibuprofen, naproxen, and diclofenac,
but have higher vascular CV risk as compared with
naproxen and placebo [14]. Given that naproxen is thought
to have the highest level of upper GI complications, any
presumed CV risk mitigation should be met with the equal
understanding of that increased GI risk.
6 Treatment Implications
It is very difficult to take population-based data and apply it
to individual patients, and as such, all published data
should be viewed in that light. Patients are very rarely
exactly at the mean or in aggregate like those in random-
ized clinical trials, so we should use the wisdom gained
from the clinical data and professional guidelines to help us
mold our individual patient decisions. Herein is one
approach informed from the current data and previously
published expert reviews [18, 19].
One way to analyze the tradeoff of NSAID-induced CV
and GI risk is by considering levels of individual patient
risk, as presented in Table 2. All patients, regardless of risk
factors, are at some GI and CV risk simply by taking the
NSAID; therefore, all patients should receive the lowest
effective dose for the shortest time period. For patients
with increasing GI risk, we know we can mitigate this risk
by using NSAIDs known to have lower intrinsic GI risk,
such as ibuprofen or celecoxib, and by using concomitant
gastroprotective agents such as proton pump inhibitors
(PPIs) or histamine H2 receptor antagonists (H2RAs)
individually or in fixed-dose combination products [18,
19]. Though NSAIDs do appear to have intrinsic differ-
ences in GI risk, this may be lost at higher dosages [14, 19].
Strategies to reduce CV risk with NSAIDs are less well
documented, and even the protective benefit of aspirin in
NSAID users is still debated. For example, the CNT ana-
lysis found that vascular event risk did not differ in aspirin
users at baseline versus non-users in those who used coxibs
[RR = 1.33 (95 % CI 0.67–2.63) vs. 1.40 (0.99–1.97)]
[14]. The increased GI risk with concomitant aspirin and
NSAIDs is well established, however [18]. Naproxen might
have a more favorable CV risk profile than coxibs and
diclofenac at higher doses, and it seems prudent to consider
this when there are no major contraindications for its use,
but we do not know if this apparent benefit is obviated or
enhanced by aspirin.
Table 1 Calculated ratios of relative risk (RRR) (95 % confidence
interval) for major vascular events with non-selective NSAIDs from
the CNT collaboration meta-analysis [14]
NSAID Comparators RRR (CI)
Ibuprofen vs. naproxen 1.55 (0.88–2.74)
Ibuprofen vs. diclofenac 1.02 (0.60–1.74)
Diclofenac vs. naproxen 1.52 (1.03–2.22)
CI confidence interval, CNT Coxib and traditional NSAID Trialists’,
NSAIDs non-steroidal anti-inflammatory drugs, RRR ratios of relative risk
Table 2 GI and CV risk assessment and potential NSAID treatment choices
Patient
risk level
No GI risk Low GI risk Moderate GI risk High GI risk
No CV
risk
Lowest effective dose of
most effective NSAID
NSAID with least GI
risk (ibuprofen)




2. Ibuprofen plus PPI/H2RAa
Low CV
risk
Low CV risk NSAID
(naproxen)
NSAID with least GI/
CV risk (ibuprofen)
1. NSAID with least GI/CV risk plus
PPI/H2RAa (ibuprofen/naproxen)
2. Celecoxib
1. Celecoxib ? PPI/H2RA




Low CV risk NSAID
(naproxen ? LDAb)
Low CV risk NSAID
(naproxen ? LDAb)
NSAID with least CV/GI risk ? PPI/
H2RA (naproxena ? LDAb)
Avoid NSAIDs if possible,
LDA ? PPIb
Adapted from references [18, 19]
CV cardiovascular, GI gastrointestinal, H2RA histamine H2 receptor antagonist, LDA low-dose aspirin, NSAID non-steroidal anti-inflammatory
drug, PPI proton pump inhibitor
a When high doses are needed, fixed-dose combination products of ibuprofen/famotidine or naproxen/esomeprazole might be warranted for
adherence benefits
b Aspirin should be administered at least 2 h before NSAID when indicated
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7 Conclusion
Clinicians should continue to use their country of origin’s
current prescribing information and individual patient
assessment to guide their decision making regarding bal-
ancing the GI and CV risk of these agents. NSAIDs have
clearly improved the quality of life of patients, as dem-
onstrated by the high usage and acceptability of these
agents, as well as their documented efficacy in clinical
trials. However, this efficacy comes with the potential price
of increased CV and GI side effects, especially at the
highest and most efficacious dosages. With the information
available today, there is insufficient evidence to conclude
from a population perspective that there are differences
between the major marketed NSAIDs in regard to their
potential for CV events. Though it does appear that the data
suggest a difference between naproxen and other NSAIDs,
it does not reach the level of substantial supportive evi-
dence. Perhaps, the ongoing PRECISION trial will, when
completed, provide further evidence to reach better
informed conclusions.
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